SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
March 20, 2024 10:00 ET
|
SERB Pharmaceuticals
Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an...
SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
July 13, 2023 08:00 ET
|
SERB Pharmaceuticals
West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard®...
SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
May 11, 2023 07:28 ET
|
SERB Pharmaceuticals
PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce...
SERB presents preclinical data showing initial efficacy of COVID-19 treatment developed with polyclonal antibody platform
October 19, 2022 08:24 ET
|
SERB Pharmaceuticals
Washington D.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed...